US2012238500A1PendingUtilityA1
Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto
Individually held — no corporate assignee on recordPriority: Oct 20, 1997Filed: Dec 19, 2011Published: Sep 20, 2012
Est. expiryOct 20, 2017(expired)· nominal 20-yr term from priority
Inventors:Elizabeth A. Wang
A61P 35/00A61P 17/14A61P 1/02A61P 17/02A61P 17/00C12N 2501/70A61Q 7/02C12N 2501/41A61K 38/1703A61K 48/00C12N 5/0627A61Q 19/00A61Q 7/00A61K 8/606C07K 14/4702A61K 31/47A61K 35/12C07K 14/461C07K 14/465C07K 14/43581A61K 31/496A61K 38/1709A61Q 19/08A61K 8/64C12N 5/0629A61K 38/17
58
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present application is directed to the discovery that preparations of hedgehog polypeptides can be used to control the formation and/or maintenance of epithelial tissue.
Claims
exact text as granted — not AI-modified1 . A method for inhibiting proliferation or differentiation of an internal epithelial cell or tissue in a post-natal mammal, comprising administering to a post-natal mammal in need thereof an amount of an agent effective to inhibit proliferation or differentiation of said epithelial cell or tissue in said mammal in need thereof, wherein the agent is a hedgehog antagonist or a patched agonist that inhibits hedgehog signal transduction.
2 . The method of claim 1 , wherein the agent inhibits proliferation of epithelial cells in the tissue.
3 . The method of claim 1 , wherein the internal epithelial cell or tissue is intestinal lining.
4 . The method of claim 1 , wherein the internal epithelial cell or tissue are esophageal cells.
5 . The method of claim 1 , wherein the post-natal mammal in need thereof is a post-natal mammal having a hyperplastic or neoplastic condition.
6 . The method of claim 5 , wherein the hyperplastic or neoplastic condition is a carcinoma.
7 . A method for treating a hyperplastic or neoplastic condition in a post-natal mammal, comprising administering to a post-natal mammal in need thereof an effective amount of an agent, wherein the agent is a hedgehog antagonist or a patched agonist that inhibits hedgehog signal transduction, and wherein the agent inhibits proliferation or differentiation of internal epithelial cells or tissue.
8 . The method of claim 7 , wherein the internal epithelial cells or tissue is intestinal lining.
9 . The method of claim 7 , wherein the internal epithelial cells or tissue are esophageal cells.
10 . The method of claim 7 , wherein said agent inhibits proliferation of internal epithelial cells.
11 . The method of claim 7 , wherein the hyperplastic or neoplastic condition is a carcinoma.
12 . The method of claim 7 , wherein the agent is administered as a therapeutic composition.
13 . A method for treating a hyperplastic or neoplastic condition of an internal epithelial tissue, comprising administering to a post-natal mammal in need thereof an effective amount of an agent, wherein the agent is a hedgehog antagonist or a patched agonist that inhibits hedgehog signal transduction.
14 . A method for increasing take rates of a skin graft in a post-natal mammal, comprising contacting said skin graft in said mammal with an effective amount of an agent, wherein said agent is a hedgehog agonist or patched antagonist that induces hedgehog signaling.
15 . A method for promoting the formation of gum tissue around natural or prosthetic teeth in a post-natal mammal, comprising administering to said mammal an effective amount of an agent, wherein the agent is a hedgehog agonist or a patched antagonist that induces hedgehog signaling.Join the waitlist — get patent alerts
Track US2012238500A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.